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Abstract
Background: Antigen sparing and cross-protective immunity are regarded as crucial in pandemic influenza vaccine
development. Both targets can be achieved by adjuvantation strategy to elicit a robust and broadened immune response.
We assessed the immunogenicity of an inactivated H5N1 whole-virion vaccine (A/Vietnam/1194/2004 NIBRG-14, clade 1)
formulated with emulsified nanoparticles and investigated whether it can induce cross-clade protecting immunity.
Methodology/Principal Findings: After formulation with PELC, a proprietary water-in-oil-in-water nanoemulsion
comprising of bioresorbable polymer/SpanH85/squalene, inactivated virus was intramuscularly administered to mice in
either one-dose or two-dose schedule. We found that the antigen-specific serum antibody responses elicited after two
doses of non-adjuvanted vaccine were lower than those observed after a single dose of adjuvanted vaccine, PELC and the
conventional alum adjuvant as well. Moreover, 5 mg HA of PELC-formulated inactivated virus were capable of inducing
higher antibodies than those obtained from alum-adjuvanted vaccine. In single-dose study, we found that encapsulating
inactivated virus into emulsified PELC nanoparticles could induce better antibody responses than those formulated with
PELC-adsorbed vaccine. However, the potency was rather reduced when the inactivated virus and CpG (an
immunostimulatory oligodeoxynucleotide containing unmethylated cytosine-guanosine motifs) were co-encapsulated
within the emulsion. Finally, the mice who received PELC/CpG(adsorption)-vaccine could easily and quickly reach 100% of
seroprotection against a homologous virus strain and effective cross-protection against a heterologous virus strain (A/
Whooper swan/Mongolia/244/2005, clade 2.2).
Conclusions/Significance: Encapsulating inactivated H5N1 influenza virus and CpG into emulsified nanoparticles critically
influences the humoral responses against pandemic influenza. These results demonstrated that the use of PELC could be as
antigen-sparing in preparation for a potential shortage of prophylactic vaccines against local infectious diseases, in
particular pandemic influenza. Moreover, the cross-clade neutralizing antibody responses data verify the potential of such
adjuvanted H5N1 candidate vaccine as an effective tool in pre-pandemic preparedness.
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Introduction
Vaccination is the best cost-effective biomedical approach in the
face of the threat of the emerging diseases like influenza epide-
mics and pandemics [1,2]. In preparedness of influenza pandemic
vaccine, two of the key challenges are to produce sufficient
quantities of vaccine in a narrowed time window and to induce
significant immunogenicity and cross-protective immunity after
vaccine injections [1–3]. Fortunately, both targets can be achieved
by using an additive substance dubbed adjuvant to elicit a robust
and broadened immune response [3].
Despite the excitement about how adjuvants work, alum (a term
for aluminum-based mineral salts) is the only adjuvant approved
by the U.S. Food and Drug Administration (FDA) in the influenza
vaccines [3]. However, highly heterogeneous, difficult to manu-
facture in a consistent and reproducible manner, and a boost
injection required to generate protection are obstacles which
limited alum in influenza vaccine use [4,5]. In fact, it is also
hypothesized that certain antigens do not adsorb well onto alum
due to the presence of the same charge on the adjuvant and
antigens. In order to reach high adsorption capacity, alum requires
preparation in a slightly acidic environment (pH=6) [6].
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oligodeoxynucleotides (ODNs) containing unmethylated cytosine-
guanosine motifs (CpG) are well-known inducers of the innate
immune response through activation of toll-like receptor (TLR)-9,
which is known an intracellular receptor within the endosomal
compartments of immune cells [7]. It has also been shown to induce
T help 1 (Th1) immune responses, characterized by secretion of
interferon (IFN)-c and the generation of IgG2a immunoglobulin
subclass in mouse model [8,9]. Although CpG was proved as an
adjuvant for a wide range of antigens [7,8], it was also observed that
CpG alone did not appear to be a potent adjuvant in some cases like
HIV and influenza antigens [9,10]. To this end, a number of studies
have shown that immune responses could be improved by
delivering CpG directly to the immune cells [10,11].
In preparation for a potential shortage of pandemic influenza
vaccine, we have previously developed the production process for
the World Health Organization (WHO) vaccine strain NIBRG-14
(recombinant clade 1 H5N1 isolate A/Vietnam/1194/2004
engineered by reverse genetics) using Madin-Darby canine kidney
(MDCK) cells, growing either in roller-bottles (Chong et al. Emergency
production of avian flu vaccines. In: Options for the control of influenza VI.
Toronto, Canada, 2007: P291.) or microcarrier-based cell culture
system [2]. We found that inactivated virus adjuvanted with alum
could elicit high virus neutralizing antibody titers in different
animal models after 2 to 3 immunizations, and also conferred
protection in mice against the wild type H5N1 challenges.
Regarding the diversity, H5N1 influenza viruses can be broadly
divisible into ten distinct lineages or clades, and multiple subclades
within clade 2. The vaccine candidate NIBRG-14 belongs to clade
1 and the strains that have continued to spread in Southeast Asia
are clade 2 [1]. For the feasibility study on a pre-pandemic
vaccination, it will be important to evaluate whether the use of
adjuvants can increase the cross-protective immune responses
against other clades of H5N1 viruses.
Recently, based on a bioresorbable diblock tri-component
copolymer poly(ethylene glycol)-block-poly(lactide-co-e-caprolac-
tone) (PEG-b-PLACL), we developed and optimized a water-in-oil-
in-water (W/O/W) multiphase emulsion-type vaccine delivery
system called PELC [12,13]. Preliminary immunogenicity studies
showed that following a single injection in mice, the PELC-
formulated 0.5 mg hemagglutinin (HA) of inactivated H5N1 virus
induced more potent antigen-specific antibodies titers than 5 mg
HA of non-adjuvanted virus. In addition, T-cell proliferative
responses and IFN-c cytokine secretion were significantly
increased when the inactivated virus was formulated with PELC
[13]. Moreover, the vaccine formulation with PELC did not skew
the immune response toward Th1 or Th2. These results indicate
that PELC can be used for effective single-dose immunization and
thus play an important role in antigen-sparing influenza pandemic
preparedness. Even though it is desirable that vaccines for
pandemic pathogens would provide protective immunity after a
single administration, one cannot conclude from mouse data that a
single injection with PELC-formulated H5N1 vaccine would be
sufficient in humans. Therefore, it would have been interesting to
see what the responses in mice are after a boost injection.
In this study, we aimed to deepen understanding the role of
PELC in vaccine immunogenicity. First, we evaluated the boosting
immune response of mice that already received a single injection of
either non-adjuvanted or PELC-adjuvanted NIBRG-14 vaccine.
We also planed to study on PELC for its ability to adjuvant
NIBRG-14 vaccine in different strategies, adsorption or encapsu-
lation. Subsequently, the improvement of the potency of PELC by
combination of immunostimulatory CpG ODNs to manipulate the
titers of protective antibodies against the homologous virus strain
and a heterologous Mongolia/244 prototype virus strain derived
by reverse genetics from a drifted H5N1 isolate (A/Whooper
swan/Mongolia/244/2005, clade 2.2) was also investigated. The
immunogenicity of a H5N1 vaccine candidate after formulated
with PELC and/or CpG was determined in mice for induction of
humoral responses following prime/boost or single-dose immuni-
zation schedules. The results were compared with those obtained
from conventional alum adjuvant.
Results
Formulating PELC with inactivated influenza virus and
CpG
Figure 1 shows the preparation of the PELC-formulated
vaccine. Initially, phase separation occurred between aqueous
solution and water-immiscible oily phase, where the aqueous
solution comprises phosphate buffered saline (PBS) and PEG-b-
PLACL, and the oily phase comprises squalene and SpanH85.
Following the emulsification, a stable and isotropic emulsion
dubbed PELC was obtained. Physiochemical studies using droplet
test and in vitro release have implied the polymer-stabilized PELC
Figure 1. Schematic presentation of the PELC-formulated
vaccine preparation. Typically, PELC-adjuvanted vaccine follows a
two-step procedure including emulsification and dispersion. In the first
step, aqueous solution containing PEG-b-PLACL and oily phase
consisting squalene and SpanH85 were homogenized to form a stable
and isotropic emulsion, PELC. In this case, oil droplets (stabilized by
hydrophilic PEG-b-PLACL) dispersed into the continuous water, and the
core oil (stabilized by lipophilic SpanH85) also entrapped aqueous. The
polymer-stabilized emulsion has high affinity to water, so that the pre-
emulsified stock could be further dispersed into aqueous solution to
form homogeneous nanoparticles in the second step.
doi:10.1371/journal.pone.0012279.g001
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squalene core (stabilized by lipophilic SpanH85) of PELC also
entrapped aqueous [12]. Due to the emulsion stock is too viscous
to be injected by syringe, a further dispersion step into the majority
of aqueous was performed to increase the fluidity, thus yielding
stable and injectable W/O/W nanoemulsion, i.e. the core oil
entrapped aqueous solution (internal aqueous solution), and the oil
droplets also dispersed into the continuous solution (external aqueous
solution). Antigen or water-soluble bioactive substance may be
dissolved either in the internal and/or external aqueous solution of
the W/O/W emulsion. For a controlled release formulation,
dissolving and encapsulating an antigen in the internal aqueous
phase has the effect of protecting the antigen. The antigens (or
biological active substances) trapped within the polymer-emulsified
oily emulsion will be released mostly by diffusion from the core oil
to the surface, but also to a lesser extent by degradation
mechanisms and emulsion breaks [12,14]. Conversely, dissolving
and entrapping an antigen in the external aqueous phase has the
effect of facilitating the expression of the antigen.
We thus defined the PELC-formulated vaccines as PELC(en-
capsulation) and PELC/CpG(encapsulation) when the antigen of
inactivated influenza virus and/or CpG were introduced in the
internal aqueous solution. Meanwhile, PELC(adsorption) and PELC/
CpG(adsorption) were represented the vaccine formulations as the
inactivated influenza virus and/or CpG were introduced in the
external aqueous solution. The vaccine design, manufacture process,
and particle size of the four emulsified vaccines were summarized in
Table 1. Homogeneous particles with mean size ranged from 400
to 500 nm were observed. Virus antigen and/or CpG are not a key
point to the particle size of the emulsions, probably due to small
amount of antigen or CpG content in the vaccine formulations. In
fact, CpG is well dissolved in the aqueous solution, while the size of
H5N1 virus suspension is about 100 nm [2].
A single-dose nanoemulsion-formulated pandemic
influenza vaccine induces more potent antigen-specific
serum antibody responses than a two-dose non-
adjuvanted vaccine
To evaluate whether the antigen-specific antibodies can be
drove by a boost immunization, BALB/c mice were immunized
with 0.5 mgo r5mg HA inactivated NIBRG-14 virus, either with
antigen in PBS or adsorbed with alum or PELC. At week 30, all
mice were boosted with dose of 0.5 mg HA H5N1 non-adjuvanted
inactivated virus vaccine. The elicited antigen-specific antibodies
are shown in Figure 2. Following the priming injection, sera from
mice vaccinated with 0.5 mg HA of non-adjuvanted inactivated
virus elicited a NIBRG-14-specific antibody IgG geometric mean
titer (GMT) less than 3,000 was detected at Week 2 and Week 4
(Figure 2A). Afterwards, it increased slowly to 6,700 at Week 8.
The highest GMT response was 32,000 at Week 12, and then
decreased to 11,000 at Week 18 and to 12,000 at Week 26. When
the same amount of inactivated virus was co-administered with
alum or PELC, the induced anti-NIBRG-14 IgG titers were
significantly higher than those induced by non-adjuvanted
inactivated virus. In both cases, the IgG titers peaked at Week 8
or Week 12 and fluctuated. However, there were no statistically
significant differences (p<1) in IgG titers between the alum- and
PELC-formulated groups. After the boosting injection, the IgG
titers were dramatically enhanced to 41,500 at Week 32 and
45,000 at Week 34 for group that primed non-adjuvanted
inactivated virus. Nevertheless, the titers were still lower than
the groups that received only one injection of alum or PELC-
formulated inactivated virus vaccine. Nonetheless, the boosting
effect was rather reduced in the groups of mice primed with
adjuvanted vaccines compared with non-adjuvanted ones. When
the amount of non-adjuvanted virus was increased to 5 mg HA, the
IgG titer was enhanced during the first 8 weeks after the priming
administration (Figure 2B), afterward, the elicited antibodies
fluctuated. Similar to the responses induced from dose of 0.5 mg
HA, the boosting effect was only found in the group of the mice
primed with 5-mg HA non-adjuvanted vaccine.
Hemagglutination inhibition (HI) assay is the most common
way to determine the efficacy of an influenza vaccine, the detected
HI titer greater than 40 was read as serological protective. We
determined HI activity using turkey erythrocytes incubated with
sera from vaccinated groups. Figure 2C shows that HI antibody
responses were elicited in BALB/c mice immunized with
inactivated NIBRG-14 virus formulated with or without adjuvant.
Overall, sera from mice vaccinated with 0.5 mg HA of non-
adjuvanted inactivated virus elicited an antigen-specific HI titer
less than 40 following a single injection. This finding implied that a
single-dose non-adjuvanted inactivated influenza vaccine probably
could not provide serological protection against the homologous
virus challenge at this dosage. Alum or PELC-adjuvanted vaccines
were capable of inducing higher HI titers than those developed
from virus alone (P,0.05). After the second injection, the HI titers
were significantly enhanced for the group the mice already
received a shot of non-adjuvanted vaccine. However, it is not the
case for the group the mice received a shot of alum- or PELC-
adjuvanted vaccine, in those groups no boosting effect was found.
When the amount of virus administrated was increased to 5 mg
HA (Figure 2D), the mean HI titer was slightly higher than 40 in
the group when the mice immunized once with inactivated virus
alone, however, the seroprotection rate (mice achieving a post-
vaccination titer $40) never reached 100%. On the other hand,
Table 1. Vaccine design, manufacture process, and particle size of four emulsions.
Formulation Emulsification process
a Dispersion process
b Particle size
c (Mean ± STD, nm)
Internal aqueous solution Oily phase External aqueous solution
PELC(encapsulation) PBS/PEG-b-PLACL/virus Squalene/SpanH85 PBS 470620
PELC/CpG(encapsulation) PBS/PEG-b-PLACL/virus/CpG Squalene/SpanH85 PBS 380640
PELC(adsorption) PBS/PEG-b-PLACL Squalene/SpanH85 PBS/virus 390670
PELC/CpG(adsorption) PBS/PEG-b-PLACL Squalene/SpanH85 PBS/virus/CpG 400630
aEmulsification process was performed using homogeniser under 6,000 rpm for 5 min.
bDispersion process was performed using test-tube rotator under 5 rpm at least 1 hr.
cThe data were represented as the mean with standard deviation (STD) of three samples.
doi:10.1371/journal.pone.0012279.t001
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reached 100% in both the 0.5 mg HA and 5 mg HA groups
indicating the merit of alum- or PELC-adjuvanted inactivated
influenza virus. Furthermore, the boosting effect could only be
found in the groups of the mice primed with non-adjuvanted or
PELC-adjuvanted vaccine (p,0.05).
Viral neutralizing (VN) assays were also performed to provide a
more functional measure of vaccine-induced immunity. As shown
in Figure 2E, neutralizing antibodies were less than 40 from sera
of mice vaccinated with 0.5 mg HA of non-adjuvanted inactivated
virus. After the boost injection, the elicited antigen-specific
neutralizing antibodies were detected 99 and 75 at Week 32 and
Week 34, in agreement with the boosting effect found in IgG and
HI titers. We also found that when the same amount of inactivated
virus was co-administered with either alum or PELC, the induced
anti-NIBRG-14 neutralizing titers were significantly higher than
those induced by non-adjuvanted inactivated virus. 5 mgH Ao f
PELC-formulated inactivated virus was capable of inducing higher
antibodies than those obtained from alum-adjuvanted virus.
Another advantage of vaccination with PELC-formulated inacti-
vated virus was also revealed after the second administration. For
non-adjuvanted vaccines, when the antigen dosage was increased
to 5 mg HA, the virus neutralizing titer was only enhanced
between Week 8 and Week 12 after the first administration
(Figure 2F). After the second injection, the boosting effect was
found in the groups of the mice primed non-adjuvanted or PELC-
adjuvanted vaccine (p,0.05). In general, the antigen-specific
serum antibody responses elicited after two doses of non-
adjuvanted vaccine were lower than those observed after a single
dose of adjuvanted vaccine, PELC and alum as well.
With respect to the induction of cross-clade neutralizing
antibodies, sera from the mice that received H5N1 clade 1-
NIBRG-14 vaccines were also incubated with a reassortant H5N1
clade 2-Mongolia/244 virus. Twelve weeks after priming injection,
only mice vaccinated intramuscularly with adjuvanted vaccines
had induced a neutralizing antibody response against the
heterologous virus, alum and PELC as well (Figure 2G).
However, high dosage (5 mg HA) was required to generate an
effective protection. Finally, we also found that the second
injection enhances the cross-neutralizing responses in the groups
of the mice have already received 0.5 mg HA of non-adjuvanted or
5 mg HA of PELC-adjuvanted vaccine (Figure 2H).
Encapsulating inactivated H5N1 influenza virus and CpG
oligodeoxynucleotides into emulsified nanoparticles
critically influences the humoral immune responses
In the first experiment, we found that there are no statistically
significant differences in antibody responses between the groups of
alum- and PELC-formulated vaccines with antigen dose of 0.5 mg
HA. We next sought to improve the potency of PELC by
combination of CpG ODN to manipulate the titers of protective
antibodies. The elicited anti-NIBRG-14 IgG titers were shown in
Table 2. Following a single injection, the NIBRG-14-specific
antibody IgG response in the group of non-adjuvanted inactivated
virus was undetectable in an initial serum dilution of 1,000 at
Week 2, and less than GMT of 3,000 were detected at Week 4.
Afterwards, it increased to 13,000 at Week 8, then to 16,000 at
Week 12. Surprisingly, when the same amount inactivated virus
was co-administered with 10 mg of CpG, the induced anti-
NIBRG-14 IgG, IgG1, and IgG2a titers were less than those
induced by non-adjuvanted inactivated virus. IgG titer less than
GMT of 1,000 was detected within 4 weeks. Nevertheless,
antibody titers were enhanced significantly when inactivated virus
adsorbed onto alum or PELC. The antibody responses induced by
PELC(adsorption) vaccine were slightly lower than those induced
by alum-adsorbed vaccine. However, this situation could be
improved when the inactivated virus were encapsulated within
PELC, especially in the early stage of the post-immunization.
Among the adjuvant combination systems, only PELC/CpG(ad-
sorption) allowed to induce better antibody responses than the
individual adjuvant (CpG or alum or PELC), whereas alum/CpG
had this effect only in the early stage after injection. However, the
potency was rather reduced when the inactivated virus and CpG
were co-encapsulated within PELC. In so far as IgG subclasses
were concerned, only PELC/CpG(adsorption) allows to bias the
ratio of titers IgG2a/IgG1 (p,0.05).
Table 2 shows the HI antibody responses in mice immunized
with different vaccine candidates formulated with or without
adjuvant. 0.5 mg HA of non-adjuvanted inactivated virus elicited
HI titers less than GMT of 20 within 4 weeks after administration.
Afterwards, it increased to 80 at week 8, then, it decreased slightly
to 63 at week 12. Similar to the findings of the IgG antibody titers,
inactivated virus formulated with CpG could not enhance the HI
titers, indicating that CpG has no adjuvanticity effect in 10-mg
dosage. On the other hand, alum- or PELC(adsorption)- vaccines
were capable of inducing higher HI titers than those obtained for
virus alone, in particular in the early stage of the post-
immunization (p,0.05); however, no significant difference was
observed between alum- and PELC(adsorption)- vaccines. Signif-
icant difference (p,0.05) was found in the group of mice that
received PELC/CpG(adsorption)- vaccines with respect to the
group with alum. However, alum/CpG did not have this
additional adjuvanticity effect. Also note that the potency of the
PELC/CpG(encapsulation)- vaccines was rather reduced than
PELC/CpG(adsorption)-ones, in agreement with the findings of
IgG titers. In terms of the longevity of the induced antibody
responses, there was no significant difference between response to
the virus alone and versus the alum- or PELC-adsorbed
formulation. In both cases, the HI titers peaked at Week 4 or
Week 8 and fluctuated. Meanwhile, the antibody levels were
induced slowly and then reached a high at Week 12 in the case of
PELC-encapsulated formulation. Considering the seroprotection
rate, only the mice received PELC/CpG(adsorption)- vaccines
could easily and quickly reach 100%.
As shown in Table 2, while alum or CpG alone does not
enhance the VN titers, the addition of PELC (either adsorption or
encapsulation) leads to much higher titers, in agreement with its
adjuvanticity found in HI titers. Also, alum adsorbed with CpG
could not increase the VN titers compared to alum alone. The
highest VN responses were elicited in the group of PELC/
CpG(adsorption) at Week 4 and in the group of PELC(encapsula-
tion) at Week 8. In overall speaking, only PELC-formulated virus
Figure 2. NIBRG-14-specific (A, B) IgG, (C, D) HI, (E, F) VN antibody responses and (G, H) Mongolia/244-specific VN antibodies in
BALB/c mice immunized by different prime/boost vaccination schedules. Mice were primed i.m. with 0.5 mgo r5mg HA of inactivated
NIBRG-14 virus, either with antigen in PBS or adsorbed with alum or PELC. At week 30, all mice were boosted i.m. with 0.5 mg HA non-adjuvanted
inactivated NIBRG-14 virus vaccine. Serum samples were collected from immunized mice and the antibody titers were determined by ELISA, HI and
VN immunoassays. The data are presented as geometric mean titers (GMT) with standard errors (SE) of eight mice per group. p-value: Comparison
between the boosting dose. The dotted horizontal line represents an HI titer of 40.
doi:10.1371/journal.pone.0012279.g002
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protective antibodies, adsorbed and encapsulated as well. In
connexion with the cross-protective immunity, only the mice
received PELC/CpG(adsorption)- vaccines could generate an
effective cross-clade neutralizing antibodies (Figure 3), a feature
similar to the findings of IgG2a/IgG1.
In summary, antigen-specific IgG, HI and VN antibody
responses elicited in BALB/c mice following a single-dose H5N1
inactivated virus vaccine immunization have found that, first, CpG
alone with 10 mg/dose has no adjuvanticity effect. Second, alum-
or PELC-adsorbed inactivated virus could induce better antibody
responses than those obtained from non-adjuvanted virus. Third,
PELC-encapsulated inactivated virus could induce better antibody
responses with respect to PELC-adsorbed vaccine. Fourth, PELC/
CpG-adsorbed virus could induce better antibody responses than
alum alone, whereas alum/CpG-adsorbed virus vaccine does not
have this effect. Fifth, PELC/CpG-encapsulated inactivated virus
could not induce better antibody responses with respect to PELC/
CpG-adsorbed vaccine. Finally, only PELC/CpG-adsorbed vac-
cine allows the host to bias the IgG2a/IgG1 ratio and also allows
to reach easily and quickly 100% of seroprotection against a
homologous virus strain and effective cross-protection against a
heterologous virus strain.
Discussion
Following injection, vaccine antigens may directly act on the host
immune cells such as antigen-presenting cells (APCs) or B cells, or
undergodegradation[15].However,thepathwaytakenmayalsobe
influenced by the presence of vaccine adjuvants, which trigger
TLRs of the immune cells or act through other pathways such as
antigen processing and presentation [9,15]. Although the mecha-
nisms of adjuvant action are often controversial, a common
mechanism attributed to alum is the delivery/depot capability, in
which mineralsalts associate with antigen and effectively increase its
biological and immunological ‘‘half-life’’ at the site of immunization
[15]. Ideally, a single injection can achieve the prime-boost
vaccination with the aid of a stepwise release of vaccine antigens.
After alum, MF59 (Novartis, [9,16]) and AS03 (GlaxoSmithKline,
[17]) are two oil-in-water (O/W) emulsion-type adjuvants with
significant potential in the development of pandemic influenza
vaccines. O/W emulsions possess better efficiency than alum due to
the induction of an early and strong immuno-competent environ-
ment at the site of injection by targeting muscle cells [16]. Studies
have shown that MF59 helps elicit strong immune memory and
sustained serological responses when used with seasonal and pre-
pandemic influenza vaccines [9]. Clinical data have also demon-
strated that pandemic H5N1vaccines formulated with AS03 induce
superior the rate of seroconversion and the titer of cross-
neutralization antibody response than those obtained either with
non-adjuvanted vaccines or alum-formulated vaccines [17]. The
WHO Strategic Advisory Group of Experts on immunization
recommended that use of O/W adjuvants was important in view of
the anticipated limited vaccine availability at global level [18].
Besides targeting antigens to the immune system, emulsions are
also capable of prolonging the duration of action of vaccine
Table 2. NIBRG-14-specific antibodies elicited in BALB/c mice following a single intramuscular dose of H5N1 inactivated virus
vaccine.
Formulation GMT ± SE (SPR, %)
No adjuvant CpG Alum
PELC
(Adsorption)
PELC
(Encapsulation) Alum/CpG
PELC/CpG
(Adsorption)
PELC/CpG
(Encapsulation)
IgG
Week 2 ,1,000 ,1,000 2,2506700 1,80061,500 5,65062,100* 4,50061,200* 10,00061,700*# 2,80061,300*
Week 4 2,8006450 ,1,000 18,00068,700* 5,65066,000 20,00068,800* 40,000622,000* 80,600617,000*# 16,000619,500*
Week 8 13,00061,700 3,0006500 64,000620,000* 14,00069,500 45,00068,500* 64,000618,000* 64,000618,000* 42,000621,000*
Week 12 16,00063,200 6,35061,900 73,500619,000* 25,00067,800 45,00068,700* 36,000617,500 128,00060*# 51,000620,000*
Subclass at Week 8
IgG1 2,80061,300 ,1,000 18,00068,400* 9,00064,400* 8,00062,200* 14,00064,400* 6,35063,000 9,00064,400*
IgG2a 8,00061,600 2,2506500 22,600625,000 4,500610,000 20,000612,000 28,000628,000 90,500617,000* 18,000611,500
IgG2a/IgG1 2.861.3 - 1.361.6 0.560.8 2.563.0 2.063.0 14.069.0*# 2.063.2
HI
Week 2 ,10 (0%) ,10 (0%) 28613
* (50%) 1016126
* (83%) 25653 (33%) 2266
* (50%) 121663
*# (100%) 26613
* (50%)
Week 4 1862 (0%) ,10 (17%) 71618
* (83%) 716102 (67%) 160653
*# (100%) 113698
* (100%) 6406436
*# (100%) 1396144
* (100%)
Week 8 80622 (83%) 1866 (33%) 202687 (100%) 113697 (83%) 254634
* (100%) 1806115 (100%) 5576443
* (100%) 2436223
* (100%)
Week 12 63620 (83%) 2060 (0%) 106625 (100%) 113641 (100%) 226682
* (100%) 80647 (83%) 3206218
* (100%) 279688
*# (100%)
VN
Week 4 ,40 ,40 ,40 ,40 ,40 ,40 72635
*# ,40
Week 8 ,40 ,40 58642 195680
* 228640
*# 47649 134619
* 57641
All mice were vaccinated once intramuscularly with dose of 0.5 mg HA H5N1 inactivated virus vaccine. Serum samples were collected from immunized mice and the
antibody titers were determined by ELISA, HI and VN immunoassays. The data are presented as geometric mean titers (GMT) with standard errors (SE) of six mice per
group. The seroprotection rate (SPR, %) is the percentage of mice achieving a post-vaccination titer $40.
*p,0.05: Comparison with the group without adjuvant at the same time point.
#p,0.05: Comparison with the group of alum at the same time point. ,1,000 means undetectable in an initial dilution of 1:1,000 on the ELISA assay system. ,10 means
undetectable in an initial dilution of 1:10 on the HI assay system. ,40 means undetectable in an initial dilution of 1:40 on the VN assay system.
doi:10.1371/journal.pone.0012279.t002
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TM ISA 51
(ISA 51, developed from SEPPIC, France), water-in-oil (W/O)
emulsions based on lipophilic mannide monooleate and mineral
oil, have been evaluated to achieve long-term protective immune
responses and to improve the innocuity of the vaccine [19]. ISA 51
is used in a non-small-cell lung cancer vaccine, CimaVax EGF, in
Cuba and Chile [15]. TiterMaxH is a squalene-based W/O
emulsion stabilized by microparticulate silica and the nonionic
block copolymer polyoxyethylene-polyoxypropylene-polyoxyethy-
lene (POE-POP-POE, known as PluronicH or PoloxamerH) [20].
However, no influenza vaccine formulated with this type of
emulsions was developed since they are crowded in the oily phase
and causing local reactions at the site of injection into animals. To
improve the injectability of such vaccines, we have previously
described the incorporation of hydrophilic polymeric emulsifier
PEG-b-PLACL in the aqueous solution to alter the water affinity of
W/O-adjuvanted vaccines, so that the pre-emulsified stock could
be re-dispersed into aqueous before injection. The ameliorated
W/O/W emulsion increases injectability and conceptually
diminishes local reactions with respect to the W/O type vaccines
produced from the same oil [12,14].
Concerning the role of adjuvants in vaccine immunogenicity,
non-adjuvanted inactivated H5N1 whole virus vaccines have
showed the priming responses of dose-dependent IgG titers with
doses ranging from 0.5 to 5 mg HA, but VN antibodies were below
the detection limitation. The data are similar to a study where the
prime/boost of Vero-cell derived H5N1 vaccines with doses
ranging from 0.001 to 3.75 mg HA antigens without adjuvant [4].
The IgG antibodies then increased strongly and VN antibodies
were also detected after the boost dose. Nonetheless, no boost
effect was detected in the cases of low-dose (0.5 mg HA antigen)
alum- and PELC-adjuvanted vaccines. Meanwhile, high-dose
(5 mg HA antigen) PELC-adjuvanted vaccine could overcome this
situation to show the boost effect. The IgG and VN data showed a
clear dose-response for a single injection of PELC-formulated
inactivated virus vaccines of 0.5 mg HA and 5 mg HA in mice, and
also after the boost dose; however, it is not the case for alum-
adjuvanted vaccines since no significant differences (p<1) in IgG,
HI and VN titers between the two doses. Regarding the adjuvant
combination systems, i.e. additional component CpG was added
to the delivery systems such as alum and PELC, the humoral
response data implied that 10 mg of CpG alone has no
adjuvanticity effect with inactivated NIBRG-14 vaccine candidate
(Table 2). We also found that alum-adsorbed CpG did not
enhance the antibody responses with respect to alum alone,
whereas PELC-adsorbed CpG induced significant immune
responses (antigen-specific antibody titers, IgG2a/IgG1 ratio,
and cross-clade neutralizing titers when compared to no adjuvant
or to alum (p,0.05); however, it is not the case when CpG was co-
encapsulated into PELC emulsion. It is beneficial of just adding
the intracellular receptor TLR9 agonist CpG to the ready-to-use
PELC emulsion as such. We have also attempted to determine
whether T-cell responses could also be manipulated when antigen
was formulated with designed adjuvant systems. Our findings
indicate that even antigen-specific T-cell proliferative responses
were significantly enhanced after immunization with PELC(en-
capsulation)- or PELC/CpG(adsorption)- adjuvanted inactivated
virus; however, the IFN-c concentration in the splenocyte
supernatants was measured at the same level as virus alone (data
not shown). It still needs to be evaluated whether the encapsulation
of influenza virion and/or CpG is beneficial on the host immune
cells such as APCs or T cells when compared to adsorption of the
same antigen and/or immunostimulator.
We conceive the preparation of a W/O/W emulsion requires
two factors: a two-step preparation process and an emulsifying
system with an intermediate HLB (hyhrophilic-lipophilic balabce)
value, as summarized in Table 3. The two-step preparation
process comprises a homogenizing (or called emulsifying) step and
a diluting (or called dispersing) step. This procedure offers the
opportunity to individually identify each parameter of the process
Figure 3. Mongolia/244-neutralizing antibodies elicited in mice following immunization with NIBRG-14 inactivated virus vaccine.
BALB/c mice were vaccinated once i.m. with dose of 0.5 mg HA NIBRG-14 inactivated virus vaccine. At week 12, sera were collected from blood and
incubated with a heterologous virus strain, Mongolia/244. An undetectable level was scored as a titer equal to 20.
doi:10.1371/journal.pone.0012279.g003
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This implies that the Novartis MF59H adjuvant, which contains
4.3% squalene, 0.5% hydrophilic emulsifier TweenH 80 (poly-
oxyethylene sorbitan monooleate, HLBTweenH80=15) and 0.5%
lipophilic emulsifier SpanH85 (HLBSpanH85=1.8), renders stable
O/W submicron emulsion via a single-step manufacture process
[9,21]. Thereafter, we found an emulsifying system of intermediate
HLB value is also required to achieve the W/O/W multi-phase
emulsion. For example, the GSK ASO3 adjuvant is a fluid O/W
emulsion, in which a pre-emulsified stock comprising squalene, a-
tocopherol, and TweenH80 was mixed with a bulk antigen before
injection [17]. This adjuvant is prepared via a two-step
manufacture process; however, it lacks an emulsifying system with
an intermediate HLB value (both squalene and a-tocopherol act as
core oil). Consequently, the development of PELC allows of
optimization of a process for making a multi-phase W/O/W
emulsion, which may trap and/or encapsulate antigens and/or
bioactive substances in the multi-phase emulsion. One should note
the canonical two-stage emulsification procedure which described
in the literature consists of two individual stirring emulsification
processes. Firstly, the W/O emulsion is prepared by emulsifying
an internal aqueous solution and a low-HLB surfactant in oil.
Secondly, the primary W/O emulsion is re-emulsified in an
external aqueous solution containing a high-HLB surfactant to produce
a W/O/W multiple emulsion. The stirring process is usually
carried out in a high-shear device to produce fine and stable
droplet, which might damage any bioactive substance to be
encapsulated or adsorbed. Here the immunological evaluation
results demonstrated that encapsulating inactivated H5N1 influ-
enza virus and/or CpG into these emulsified nanoparticles
critically influences the host immune responses. To extend this
aspect to the temporary therapeutic applications in sustained
delivery, the aqueous solution may be an aqueous medium alone,
such as PBS, or an aqueous medium containing an antigen or a
bioactive substance such as peptides, anticancer agents, hormones,
or other active agents such as antibiotics or antiparasitics. The
antigen or the bioactive substance may be incorporated into the
multiphase emulsion via dissolving in either the oily or the aqueous
phase. Last but not least, it is also worth noting that the antigens
are exposed low shear stress (6,000 rpm) during emulsification
processing of PELC emulsion stock.
So far as the safety issue is concerned, a claim was made that
adjuvanted vaccines foster either accepted or hypersensitive
autoimmune diseases due to boost the immune system of the
body too much [3]. Of note, clinical studies also found that
vaccines containing CpG arise in a severe autoimmune disease,
Wegener’s granulomatosis, in which blood vessels become
inflamed [3]. Thus, encapsulating small amount of such
immunostimulatory adjuvant into biological inert vehicle of PELC
is a probable strategy to improve the innocuity of vaccines. From a
viewpoint of emulsion composition, the core oil selected, squalene,
is a naturally occurring oil produced by plants and is also
produced abundantly by human beings, notably the precursor of
cholesterol and steroid hormones synthesized in the liver and the
skin [22]. Although some studies indicated that anti-squalene
antibodies were detectable in the sera of individuals with the so-
called Gulf War syndrome, anti-squalene antibodies are not
increased by immunization with vaccines with the squalene-in-
water emulsion was also reported [22]. The excipient use of
SpanH85 in the oily phase is also positively indicated, as it is an
emulsification agent widely used in pharmaceutical formulations
and also in licensed human vaccines [9,21]. Eventually, biode-
gradable PEG-b-PLACL is derived from FDA-approved PEG,
polylactides, and poly(e-caprolactone) [12,14]. It allows stabiliza-
tion of emulsion particles during storage but allows disintegration
of the system post-injection [13]. Consequently, PELC-formulated
vaccines comprising the highly safe components manifested its
potential safety and efficacy.
The data presented here demonstrate that the antigen-specific
serum antibody responses elicited after two doses of non-
adjuvanted vaccine were lower than those observed after a single
dose of adjuvanted vaccine, PELC and alum as well. Moreover,
encapsulation of inactivated H5N1 influenza virus and CpG into
emulsified nanoparticles critically influences the antigen-specific
and cross-clade serological antibody responses against pandemic
influenza; the use of PELC could be more adaptable in
preparation for a potential shortage of prophylactic vaccines
against local infectious diseases, in particular pandemic influenza.
Further investigations are under way to examine the micro-
encapsulation technology for a single-dose multivalent vaccine
against influenza and local infectious diseases where they co-exist.
Materials and Methods
Vaccine preparation
The vaccine used in this study was a formalin-inactivated whole
virus vaccine, NIBRG-14 (kindly supplied by the UK National
Institute of Biological Standard and Control, NIBSC), derived
from a reassortant H5N1 vaccine strain containing modified HA
and neuraminidase (NA) from the highly pathogenic avian
influenza strain A/Vietnam/1194/2004 virus. The NIBRG-14
vaccine viruses were grown in eggs by the NIBSC and supplied to
Taiwan Centers for Disease Control (CDC). Taiwan CDC further
amplified the NIBRG-14 for four generations in eggs and then
transferred to Vaccine Research and Development Center
(VRDC) of National Health Research Institutes (NHRI). In
VRDC, the received NIBRG-14 was propagated in serum-free
media (Cesco, Taiwan) and in the MDCK cell culture-based roller
bottle technology. The manufacturing space is specified as P2+
facility with one positive pressure cell culture room, two negative
pressure rooms for virus growth and downstream purification
Table 3. Comparison of components, dispersion type, and manufacture process of selected examples of emulsions.
Adjuvant Company Components Dispersion type Manufacture process
Core oil Hydrophilic Emulsifier Lipophilic Emulsifier
ISA51 SEPPIC Drakeol - Mannide monooleate W/O Single-step emulsification process
MF59 Novartis Squalene TweenH80 SpanH85 O/W Single-step emulsification process
AS03 GlaxoSmithKline Squalene/a-tocopherol TweenH80 - O/W Emulsification-dispersion process
PELC VRDC, NHRI Squalene PEG-b-PLACL SpanH85 W/O/W Emulsification-dispersion process
doi:10.1371/journal.pone.0012279.t003
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MDCK cells were purchased from Food Industry Research and
Development Institute (FIRDI), Taiwan. Master and working cell
banks were established following current Good Manufacturing
Practices (cGMP) guidelines. Formalin-inactivated vaccines were
prepared with 0.1% formalin at 37uC for 24 hr. We had
performed plaque assay based on plaque forming unit (PFU) in
MDCK cells and the TCID50 (50% tissue culture infective dose)
assay based on the cytopathic effect to evaluate whether there was
incomplete formalin inactivation during storage. After the
sterilization through a 0.22 mm filter membrane, the HA content
of the vaccine bulk was determined by single-radial diffusion
(SRD) assay with the standard antigen and antiserum from
NIBSC. The antigen medium was prepared with particular HA
concentration of the vaccine bulk which is diluted in the phosphate
buffered saline (PBS).
Adjuvant preparation
Murine CpG ODN was synthesized by Invitrogen Taiwan Ltd
and given as a 10 mg per dose dissolved in the PBS or in the
antigenic media. The CpG ODN sequence used was 59-TCC
ATG ACG TTC CTG ACG TT-39 with all phosphorothioate
backbones. Alum (aluminum phosphate) suspension was kindly
provided from Taiwan CDC and given as a 300 mg per dose in the
acidic media (pH=6).
PELC is a squalene W/O/W nanoemulsion stabilized by
SpanH85 (sorbitan trioleate, Sigma-Aldrich, Steinheim, Germany)
and PEG-b-PLACL, the latter consisting 75 wt-% of hydrophilic
bioabsorbable PEG and 25 wt-% of lipophilic biodegradable
PLACL with molecular weight of 7,000 daltons as previously
described [12–14]. Briefly, 120 mg of PEG-b-PLACL, 0.8 mL of
aqueous solution (internal aqueous solution), and 1.1 mL of oily
solution consisting of squalene (Sigma-Aldrich, Steinheim, Ger-
many) and SpanH85 (85/15 v/v) were emulsified using Poly-
tronHPT 3100 homogeniser (Kinematica AG, Switzerland) under
6,000 rpm for 5 min. The emulsified PELC formulation was
stored at 4uC until use. PELC-formulated vaccine was investigated
by re-dispersing 200 mL of stock emulsion into 1800 mLo f
aqueous solution (external aqueous solution) and mixed with a test-
tube rotator (Labinco LD-79, Netherlands) under 5 rpm at least
1 hr before injection. Inactivated influenza virus and/or CpG
were introduced either in the internal aqueous solution or the external
aqueous solution to yield a PELC-encapsulated or adsorbed influenza
vaccine, respectively. The size distribution of the emulsions was
investigated by microscopic aspects (Olympus DP70 Digital
Microscope Camera, Melville, NY, USA) and the laser light
scattering technique using a Brookhaven 90 plus particle size
analyzer (Brookhaven Instruments Limited, New York, USA).
Ethics statement and immunizations
All experiments were conducted in accordance with the
guidelines of Laboratory Animal Center of NHRI. The animal
use protocols have been reviewed and approved by the NHRI
Institutional Animal Care and Use Committee (IACUC). Five
weeks old female BALB/c mice were obtained from the National
Laboratory Animal Breeding and Research Center (Taipei,
Taiwan) and acclimatized for at least one week at the NHRI
animal facility prior to use. To investigate the potency of candidate
H5N1 influenza vaccine, we designed two immunological
experiments. In the first experiment, mice were primed intramus-
cularly (i.m.) with one of two different doses (0.5 mgo r5mg HA),
either with antigen in PBS or adsorbed with alum or PELC. At
week 30, all mice were boosted i.m. with dose of 0.5 mg HA H5N1
non-adjuvanted inactivated virus vaccine. In the second experi-
ment, all mice were vaccinated i.m. once with 0.5 mg HA given
with or without adjuvant. Serum samples were collected from
immunized mice and the antibody titers were determined by
enzyme-linked immunosorbent assay (ELISA), HI titration, and
VN assays.
ELISA immunoassay
The presence of NIBRG-14-specific antibodies in the sera was
determined by ELISA. In brief, 100 mL of dilute inactivated virus
(1 mg/mL) were coated in 96-well microtiter plates with 0.05 M
carbonate buffer (pH 9.6, Sigma, St. Louis, MO, USA) by
overnight incubation at room temperature. Coated plates were
washed once with PBS containing 0.05% TweenH20 (Sigma, St.
Louis, MO, USA) and then blocked with 1% bovine serum
albumin (BSA, Sigma, St. Louis, MO, USA) in PBS at room
temperature for 2 h. Diluted sera (starting dilution 1:1000, serial
two-fold serum dilutions) from immunized animals were applied to
wells at room temperature for 2 h. Followed by HRP-conjugated
goat anti-mouse IgG (ICN Cappel, Aurora, Ohio, USA, 1:5,000),
the assay was developed with substrate solution 2,29-azino-di(3-
ethyl-benzthiazoline-6-sulfonate (ABTSH Peroxidase, KPL, MD,
USA) for 20 min at room temperature (avoid light). Plates were
read at 405 nm using an ELISA plate reader (Thermo MultiskanH
spectrophotometer, Vantaa, Finland). For IgG subclass determi-
nation, 100 mL of HRP-rabbit anti-mouse IgG1 (AbD Serotec,
Kidlington, UK, 1:5,000) or HRP-rabbit anti-mouse IgG2a (AbD
Serotec, Kidlington, UK, 1:2,000) was added. The titers were
determined from the reciprocal of the final dilution that gave an
optical of two-fold absorbance of pre-immune sera. For calculation
purposes, an undetectable level was scored as a titer equal to 500.
HI titration
The principle of the HI test is based on the ability of specific
anti-influenza antibodies to inhibit hemagglutination of turkey red
blood cells (RBCs) by influenza virus HA. Non-specific inhibitors
of agglutination were removed by heat treatment and addition of
receptor-destroying enzyme. After pretreatment, serum samples
(two-fold dilutions starting with an initial dilution of 1:10) were
incubated with four HA units of influenza strain. Turkey RBCs
were then added and the inhibition of agglutination was scored.
The serum titer was expressed as the reciprocal of the highest
dilution that showed complete inhibition of HA. For calculation
purposes, an undetectable level was scored as a titer equal to five.
The seroprotection rate (SPR, %) was calculated from the
proportion of mice achieving a post-vaccination titer $40.
VN assay
The 200 TCID50 per well of NIBRG-14 virus were incubated
with two-fold-diluted mice sera at a starting dilution of 1:40.
Mixtures of virus and serum were transferred to monolayers of
MDCK cells and incubated at 37uC and 5% CO2 for 4 days. The
neutralizing titer was defined as the reciprocal of the highest serum
dilution at which the infectivity of the H5N1 virus’ 200 TCID50
for MDCK cells was completely neutralized in 50% of the wells.
Infectivity was identified by the presence of cytopathy on Day 4
and the titer was calculated using the Reed-Muench method. For
calculation purposes, an undetectable level was scored as a titer
equal to 20. To assess cross-protective immunogenicity, serum
samples were also tested with a heterologous Mongolia/244 (ST/
NIAID, St Jude Children’s Research Hospital, National Institute
of Allergic and Infectious Disease, USA) derived by reverse
genetics from a drifted H5N1 clade 2.2 isolate A/Whooper swan/
Mongolia/244/2005 and H1N1 A/Puerto Rico/8/34.
Encapsulating Virus and CpG
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Statistical significance (p,0.05) was determined by performing
two-tailed Student’s t-test on log-transformed values, using
Microsoft Excel.
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